Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Genge, Angela; van den Berg, Leonard H; Frick, Glen; Han, Steve; Abikoff, Cori; Simmons, Adam; Lin, Qun; Patra, Kaushik; Kupperman, Erik; Berry, James D

Genge, Angela; van den Berg, Leonard H; Frick, Glen; Han, Steve; Abikoff, Cori; Simmons, Adam; Lin, Qun; Patra, Kaushik; Kupperman, Erik; Berry, James D.

Afiliación

Genge A; McGill University, Montréal, Québec, Canada.
van den Berg LH; University Medical Center Utrecht, Utrecht, the Netherlands.
Frick G; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
Han S; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
Abikoff C; Now with Takeda Pharmaceuticals, Cambridge, Massachusetts.
Simmons A; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
Lin Q; Now with Takeda Pharmaceuticals, Cambridge, Massachusetts.
Patra K; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
Kupperman E; Now with Alector, West Hartford, Connecticut.
Berry JD; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.

JAMA Neurol ; 80(10): 1089-1097, 2023 Oct 01.

Article en En | MEDLINE | ID: mdl-37695623

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: JAMA Neurol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google